Compare Alcon AG (ALC) vs Applovin Corporation (APP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Applovin Corporation — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Applovin Corporation trades at $522 (market cap $177.37B). The key difference: Applovin Corporation is far larger — about 5.4× Alcon AG's market cap, and Alcon AG pays a 0.54% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| ALC | APP | |
|---|---|---|
Market Cap | $32.69B | $177.37B |
Sector | Health | Technology |
52-Week High | $92.22 | $733.60 |
52-Week Low | $62.02 | $335.10 |
Enterprise Value | $36.28B | $178.12B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
AppLovin (APP) trades at $543.79, up 3.17% with strong technical momentum and bullish analyst sentiment. The stock demonstrates exceptional profitability with 64.29% net income margins and consistent earnings beats. Recent Q1 2026 results showed $3.56 EPS beating expectations, while technical indicators signal bullish momentum with key resistance at $554. The company's AI-powered advertising platform drives robust revenue growth, with 2026 revenue projected at $6.2 billion.
AppLovin presents compelling growth potential with 88% analyst buy ratings and $644.09 consensus price target, offering 18% upside. However, premium valuations (P/E 47.29, P/S 30.03) and competitive pressures in mobile advertising represent key risks. The upcoming Q2 2026 earnings on August 5th will be crucial for validating the AI growth narrative and sustaining current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →
